Vincent Goeb

Summary

Country: France

Publications

  1. ncbi Potential role of arthroscopy in the management of inflammatory arthritis
    V Goeb
    Section of Musculoskeletal Disease, Chapel Allerton Hospital, Leeds Institute of Molecular Medicine, University of Leeds, United Kingdom
    Clin Exp Rheumatol 30:429-35. 2012
  2. ncbi Association between the TNFRII 196R allele and diagnosis of rheumatoid arthritis
    Vincent Goeb
    Rheumatology Department, University Hospital of Rouen, Rouen, France
    Arthritis Res Ther 7:R1056-62. 2005
  3. ncbi Clinical significance of autoantibodies recognizing Sjögren's syndrome A (SSA), SSB, calpastatin and alpha-fodrin in primary Sjögren's syndrome
    V Goeb
    Department of Rheumatology, Rouen University Hospital and Inserm U519 IFRMP23, Institute for Biomedical Research, University of Rouen, Rouen, France
    Clin Exp Immunol 148:281-7. 2007
  4. ncbi Post-partum sacral fracture associated with heparin treatment
    Vincent Goeb
    Department of Rheumatology, Rouen University Hospital and Inserm U905 IFRMP 23, Institute for Biomedical Research, University of Rouen, 76031 Rouen Cedex, France
    Clin Rheumatol 27:S51-3. 2008
  5. ncbi Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis
    V Goeb
    Department of Rheumatology, Rouen University Hospital and Inserm, Institute for Biomedical Research, University of Rouen, France
    Rheumatology (Oxford) 47:1208-12. 2008
  6. ncbi Candidate autoantigens identified by mass spectrometry in early rheumatoid arthritis are chaperones and citrullinated glycolytic enzymes
    Vincent Goeb
    Department of Rheumatology and Inserm Unit 905, IFRMP 23, Institute for Biomedical Research, University of Rouen, Rouen University Hospital, Rouen 76031 cedex, France
    Arthritis Res Ther 11:R38. 2009
  7. ncbi Diagnostic and prognostic usefulness of antibodies to citrullinated peptides
    Vincent Goeb
    Service de Rhumatologie, Institut de recherche biomédicale, CHU Hôpitaux de Rouen, France
    Joint Bone Spine 76:343-9. 2009
  8. ncbi Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study
    Damien Fouache
    Department of Pharmacy, University of Medicine Pharmacy, Rouen University Hospital and Inserm U905 IFRMP 23, Institute for Biomedical Research, University of Rouen, Rouen, France
    Rheumatology (Oxford) 48:761-4. 2009
  9. ncbi A 3 mg/kg starting dose of infliximab in active spondyloarthritis resistant to conventional treatments is efficient, safe and lowers costs
    Ginette Tenga
    Department of Pharmacy, Rouen University Hospital, 76031 Rouen Cedex, France
    Joint Bone Spine 78:50-5. 2011
  10. ncbi Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology
    Thierry Lequerre
    Department of Rheumatology, Rouen University Hospital, Rouen, France
    J Rheumatol 33:1307-14. 2006

Detail Information

Publications19

  1. ncbi Potential role of arthroscopy in the management of inflammatory arthritis
    V Goeb
    Section of Musculoskeletal Disease, Chapel Allerton Hospital, Leeds Institute of Molecular Medicine, University of Leeds, United Kingdom
    Clin Exp Rheumatol 30:429-35. 2012
    ..Assessment of arthroscopic derived synovial biopsies has potential to play an important role in management of early IA in the future...
  2. ncbi Association between the TNFRII 196R allele and diagnosis of rheumatoid arthritis
    Vincent Goeb
    Rheumatology Department, University Hospital of Rouen, Rouen, France
    Arthritis Res Ther 7:R1056-62. 2005
    ..Our findings suggest that the TNFRII 196R allele may be associated with RA diagnosis but that it does not predict early radiographic progression or functional severity in patients with very early, unclassified arthritis...
  3. ncbi Clinical significance of autoantibodies recognizing Sjögren's syndrome A (SSA), SSB, calpastatin and alpha-fodrin in primary Sjögren's syndrome
    V Goeb
    Department of Rheumatology, Rouen University Hospital and Inserm U519 IFRMP23, Institute for Biomedical Research, University of Rouen, Rouen, France
    Clin Exp Immunol 148:281-7. 2007
    ..Positivity of anti-60-kDa SSA, anti-SSB, anti-calpastatin, IgA and IgG anti-alpha-fodrin antibodies is not associated with pSS clinical and biological severity...
  4. ncbi Post-partum sacral fracture associated with heparin treatment
    Vincent Goeb
    Department of Rheumatology, Rouen University Hospital and Inserm U905 IFRMP 23, Institute for Biomedical Research, University of Rouen, 76031 Rouen Cedex, France
    Clin Rheumatol 27:S51-3. 2008
    ..MRI seems to be the key exam because it is able to detect and stage fractures or microfractures...
  5. ncbi Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis
    V Goeb
    Department of Rheumatology, Rouen University Hospital and Inserm, Institute for Biomedical Research, University of Rouen, France
    Rheumatology (Oxford) 47:1208-12. 2008
    ..To evaluate the predictive value of TNFRII 196R, PTPN22 1858T and HLA-shared epitope (SE) alleles, RFs and anti-citrullinated protein antibodies (ACPAs) for RA diagnosis in a cohort of patients with very early arthritis...
  6. ncbi Candidate autoantigens identified by mass spectrometry in early rheumatoid arthritis are chaperones and citrullinated glycolytic enzymes
    Vincent Goeb
    Department of Rheumatology and Inserm Unit 905, IFRMP 23, Institute for Biomedical Research, University of Rouen, Rouen University Hospital, Rouen 76031 cedex, France
    Arthritis Res Ther 11:R38. 2009
    ..The aim of our study was to identify new early rheumatoid arthritis (RA) autoantibodies...
  7. ncbi Diagnostic and prognostic usefulness of antibodies to citrullinated peptides
    Vincent Goeb
    Service de Rhumatologie, Institut de recherche biomédicale, CHU Hôpitaux de Rouen, France
    Joint Bone Spine 76:343-9. 2009
    ..The presence of ACPAs predicts poorer functional and structural outcomes, and ACPA titers respond to some of the medications used in RA. Therefore, ACPA titers should be determined at regular intervals throughout follow-up...
  8. ncbi Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study
    Damien Fouache
    Department of Pharmacy, University of Medicine Pharmacy, Rouen University Hospital and Inserm U905 IFRMP 23, Institute for Biomedical Research, University of Rouen, Rouen, France
    Rheumatology (Oxford) 48:761-4. 2009
    ..This retrospective study aimed to describe the different PAEs that have occurred in a population of SpA patients treated with anti-TNF drugs, and to determine whether they are drug specific...
  9. ncbi A 3 mg/kg starting dose of infliximab in active spondyloarthritis resistant to conventional treatments is efficient, safe and lowers costs
    Ginette Tenga
    Department of Pharmacy, Rouen University Hospital, 76031 Rouen Cedex, France
    Joint Bone Spine 78:50-5. 2011
    ..We assessed the efficacy, tolerance and cost of a 3 mg/kg starting dose of infliximab for ankylosing spondylitis (AS) and psoriatic arthritis (PsA)...
  10. ncbi Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology
    Thierry Lequerre
    Department of Rheumatology, Rouen University Hospital, Rouen, France
    J Rheumatol 33:1307-14. 2006
    ..To suggest recommendations for management of acute infusion reactions induced by infliximab in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA)...
  11. ncbi Smoking and inflammatory diseases
    Olivier Vittecoq
    Department of Rheumatology, Rouen University Hospital and Inserm U905, Rouen, France
    Best Pract Res Clin Rheumatol 22:923-35. 2008
    ..In both diseases, smoking might interfere with drug efficacy...
  12. ncbi Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature
    Jean Marie Berthelot
    Service de Rhumatologie, Hotel Dieu, CHU Nantes, 44093, Nantes Cedex 01, France
    Joint Bone Spine 76:28-34. 2009
    ..To report on the outcome of 15 cases of pregnancies in women treated with anti-TNF drugs during conception or pregnancy..
  13. ncbi Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?
    Benazir Saleem
    Leeds Institute of Molecular Medicine, University of Leeds, Chapel Allerton Hospital, Chapeltown Road, Leeds, UK
    Ann Rheum Dis 69:1636-42. 2010
    ..However, there are no guidelines regarding cessation of therapy. There is a need for markers predictive of sustained remission following cessation of TNF blocker therapy...
  14. ncbi [Goals of therapy in rheumatoid arthritis]
    Xavier Le Loet
    Service de Rhumatologie, CHU Hôpitaux de Rouen, 76031 Rouen Cedex, France
    Rev Prat 62:1094-8. 2012
    ....
  15. ncbi Role for magnetic resonance imaging in coccydynia with sacrococcygeal dislocation
    Anne Priscille Trouvin
    Service de Rhumatologie, CHU Hôpitaux de Rouen, 1, rue de Germont, 76031 Rouen Cedex, France
    Joint Bone Spine 80:214-6. 2013
    ..One of the patients accepted this procedure and subsequently reported complete resolution of the symptoms...
  16. ncbi Atypical forms of syphilis: two cases
    Gilles Avenel
    Service de Rhumatologie, CHU Hôpitaux de Rouen, and INSERM, U905, IFRMP23, Institut de Biologie Clinique, Rouen, France
    Joint Bone Spine 76:293-5. 2009
    ..Neither patient was infected with the HIV...
  17. ncbi Costimulation blockade in rheumatic diseases: where we are?
    Vincent Goeb
    Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, Leeds LS7 4SA, UK
    Curr Opin Rheumatol 21:244-50. 2009
    ..To describe the mechanisms of action of abatacept (CTLA4-Ig) and summarize the evidence of its efficacy and safety in rheumatoid arthritis (RA) and other rheumatic diseases such as juvenile idiopathic arthritis (JIA)...
  18. ncbi TNF alpha antagonist therapy and safety monitoring
    Thao Pham
    Rheumatology Department, CHU Sainte Marguerite, Marseille, France
    Joint Bone Spine 78:15-185. 2011
    ..To develop and/or update fact sheets about TNFα antagonists treatments, in order to assist physicians in the management of patients with inflammatory joint disease...
  19. ncbi IL-7 and lymphopenia
    Frederique Ponchel
    Leeds Institute of Molecular Medicine, Section of Musculoskeletal Disease, The University of Leeds, Leeds, UK
    Clin Chim Acta 412:7-16. 2011
    ..Anti- IL-7 is on the other hand proposed to treat conditions where IL-7 may play a more direct role in pathogenesis such as autoimmune disease like Rheumatoid Arthritis, Multiple Sclerosis or Inflammatory Bowel disease...